Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689884 · ClinicalTrials.gov registry record · NA
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00689884: Clinical Trial NA study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00689884 is a NA study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00689884, a NA study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to Pegfilgrastim use in the mobilization of autologous PBSCs. Also to determine the side effects of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells.
Primary Outcome
Outcome was not reported. The study was terminated for lack of enrollment. Data collection was terminated. No data analysis was performed.
Interventions
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-01 |
| Phase | NA |
Why NCT00689884 stopped before completion
NCT00689884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Pegfilgrastim is the first listed.
NCT00689884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00689884 about?
NCT00689884 is a clinical study titled "Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies". The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to Pegfilgrastim use in the mobilization of autologous PBSCs. Also to determine the...
What is the current status of trial NCT00689884?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2007-01. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00689884?
The interventions under investigation include: Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT00689884?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00689884's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia